Comparative Pharmacology
Head-to-head clinical analysis: MIRALUMA versus SODIUM FLUORIDE F 18.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRALUMA versus SODIUM FLUORIDE F 18.
MIRALUMA vs SODIUM FLUORIDE F-18
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MIRALUMA (garadacimab) is a monoclonal antibody that binds to activated factor XII (FXIIa) and inhibits its activity, thereby blocking the contact activation pathway of the coagulation cascade. This prevents the generation of bradykinin, reducing vascular permeability and swelling in hereditary angioedema (HAE).
Positron-emitting radionuclide used for bone imaging; fluoride ion is incorporated into bone matrix via chemisorption onto hydroxyapatite crystals, reflecting blood flow and osteoblastic activity.
MIRALUMA (mirvetuximab soravtansine) is administered intravenously at 6 mg/kg adjusted ideal body weight (AIBW) once every 3 weeks until disease progression or unacceptable toxicity.
2-10 mCi (74-370 MBq) intravenous bolus injection, single dose for positron emission tomography (PET) bone imaging.
None Documented
None Documented
20 hours; prolonged to 30-40 hours in renal impairment requiring dose adjustment
The terminal elimination half-life is approximately 2-4 hours. Clinically, this allows for imaging within 1-3 hours post-injection.
90% renal as unchanged drug; 10% biliary/fecal
Renal (primarily). Approximately 70% of the administered dose is excreted unchanged in urine within 24 hours. Less than 10% is excreted in feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical